Note: Descriptions are shown in the official language in which they were submitted.
CA 02090011 2001-08-20
PC T~~i ~ 91./ 0417 ~+
3 0 SEP19
92
Substitute Sheet
20~~~~
-1-
TITLE OF THE INVENTI0~1:
Anti-Intlamnato~y Facto.
Method of Isolation, and Use
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to an anti-inflammatory
factor, a process for its production in substantially pure form,
and a method for its use in the treatment of inflammation.
Description of the Background Art
Inflammation, as defined in Dorland's Medical Dictionary,
is "a localized protective response elicited by injury or
.~.~c.c~
\, ~U ~ ~' ~~
WO 9~:/04036 PCT/US91/04174
2090011
_2_
destruction of tissues which serves to destroy, dilute or wall
off both the injurious agent and the injured tissue." It is
characterized by fenestration of the microvascuiature,
leakages of the elements of blood into the interstitial
spaces, and migration of leukocytes into the inflamed tissue.
On a macroscopic level, this is usually accompanied by the
familiar clinical signs of erythema, edema, tenderness (hyper-
algesia), and pain. O~uring this complex response, chemical
mediators such as histamine, 5-hydroxytryptamine, various
chemotactic factors, bradykinin, leukotrienes, and
prostaglandins are liberated locally. Phagocytic cells
migrate into the area, .and cellular lysosomal membranes may be
ruptured, releasing lyi:ic enzymes. All of these events may
contribute to the inflammatory response.
Inflammation in patients with rheumatoid arthritis
probably involves the combination of an antigen (gamma
globulin) with an antic>ody (rheumatoid factor) and complement
causing the local release of chemotactic factors that attract
leukocytes. The leukocytes phagocytose the complexes of
antigen-antibody and complement and also release the many
enzymes contained in their lysosomes. These lysosomal enzymes
then cause injury to cartilage and other tissues, and this
furthers the degree of inflammation. Cell-mediated immune
reactions may also be involved. Prostaglandins are also
released during this process.
Prostaglandins, which are likely to be generated in
inflarr~nation, cause erythema and increase local blood flow.
Two important vascular effects of prostaglandins are not
generally shared by other mediators of inflammation - a long-
lasting vasodilator action and a capacity to counteract the
vasoconstrictor effects of substances such as norepinephrine
and angiotensin.
A number of mediators of inflammation increase vascular
permeability (leakage) in the post-capillary and collecting
WO 92/04035 PCT/i.JS91/0417a
20~00~.1
-3-
venules. In addition, migration of leukocytes into an
inflamed area is an important aspect of the inflammatory
process.
The Arthus reaction is an inflammatory response brought
about by the formation of immune complexes at subcutaneous
sites where an antigen complexes with antibody to that
antigen. Neutrophils characteristically attach to the Fc
portion of the immunoglobulin complex that forms at the
subcutaneous injection site where they release digestive
enzymes, causing visible acute inflammation. Thus the
reaction is primarily neutrophil-mediated and agents that
effect the development of the reaction do so via an effect on
these cells.
There are several pathways whereby an agent might
interfere with neutrophil migration from the blood vessels to
an inflammatory site. One likely pathway is the inhibition
of margination, the reversible "sticking" of inflammatory
cells to the endothelial cell lining of the blood vessel wall.
In the normal state about 50% of neutrophils are reversibly
adhered, but during an acute inflammatory response, adhesion
becomes much stronger and is a key step in the process of
neutrophil migration. While prostaglandins are unlikely to
be directly involved in the chemotactic response, another
product of the metabolism of arachidonic acid, leukotriene, is
~ very potent chemotactic substance.
The anti-inflammatory response is any response
characterized by inflammation as defined above. It is well
known to those skilled in the medical arts that the
inflananatory response causes much of the physical discomfort,
i.e., pain and loss of function, that has come to be
associated with different diseases and injuries. Accordingly,
it is a cortmon medical practice to administer pharmacological
agents which have the effect of neutralizing the inflammatory
response. Agents having these properties are classified as
WO 92/04035 PCT/1.~59110417a
2090~~~-
-4-
anti-inflatrnnatory drugs. Anti-inflammatory drugs are used for
the treatment of a wide spectrum of disorders, and the same
drugs are often used to treat different diseases. Treatment
with anti-inflartmatory .drugs is not for the disease, but most
often for the symptom, i.e., inflammation.
The anti-inflammatory, analgesic, and anti-pyretic drugs
are a heterogeneous group of compounds, often chemically
unrelated, which nevertheless share certain therapeutic
actions and side-effects. Corticosteroids represent the most
widely used class of compounds for the treatment of the anti-
inflammatory response. Proteolytic enzymes represent another
class of compounds which are thought to have anti-inflammatory
effects. Hormones which directly or indirectly cause the
adrenal cortex to produce and secrete steroids represent
another class of anti-inflammatory compounds. A number of
non-hormonal anti-inflammatory agents have been described.
Among these, the most widely used are the salicylates.
Acetylsalicylic acid, or aspirin, is the most widely
prescribed analgesic-antipyretic and anti-inflammatory agent.
Examples of steroidal and non-steroidal anti-inflammatory
agents are listed in the Physician's Desk Reference, 1987 (see
pp. 207 and 208 for an index of such preparations).
The natural and synthetic corticosteroid preparations
cause a number of severe side effects, including elevation of
blood pressure, salt and water retention, and increased
potassium and calcium excretion. Moreover, corticosteroids
may mask the signs of infection and enhance dissemination of
infectious microorganisms. These hormones are not considered
safe for use in pregnant women, and long-term corticosteroid
treatment has been associated with gastric hyperactivity
and/or peptic ulcers. Treatment with these compounds may also
aggravate diabetes mellitus, requiring higher doses of
insulin, and may produce psychotic disorders. Hormonal anti-
inflammatory agents which indirectly increase the production
WO 92/04035 PCT/US91/0417a
20~001~
-5-
of endogenous corticosteroids have the same potential for
adverse side-effects.
The non-hormonal anti-inflammatory agents are synthetic
biochemical compounds which can be toxic at high doses with a
wide spectrum of undesirable side-effects. For example,
salicylates contribute to the serious acid-base balance
disturbances that characterize poisoning by this class of
compounds. Salicylates stimulate respiration directly and
indirectly. Toxic doses of salicylates cause central
respiratory paralysis as well as circulatory collapse
secondary to vasomotor depression. The ingestion of
salicylate may result in epigastric distress, nausea, and
vomiting. Salicylate-induced gastric bleeding is well known.
Salicylates can produce hepatic injury, and lead to a
prolongation of clotting time. Therefore, aspirin should be
avoided in patients with severe hepatic damage, hypoprothrom-
binemia, vitamin K deficiency, or hemophilia, because the
inhibition of platelet hemostasis by salicylates can result in
hemorrhage. Salicylate intoxication is common, and over
10,000 cases of serious salicylate intoxication are seen in
the United States every year, some of them being fatal, and
many occurring in children. See Goodman and Gilman's The
Pharmacolo4ical Basis of Therapeutics, 7th Ed., 1985.
Accordingly, in spite of the large number of anti-inflammatory
agents that are currently available, there still exists a need
for a safe, effective anti-inflammatory product which is free
of side-effects and adverse reactions.
If a natural food product, such as one derived from milk,
for example, could be obtained having anti-inflammatory
effects, it would be an easily administrable, readily
available, safe therapeutic composition.
It has been known in the prior art to produce milks
having a variety of therapeutic effects. Beck, for example,
has disclosed a milk containing antibody to Streptococcus
CA 02090011 2001-08-20
WO 9: /04035 PCT/US91 /0417a
2t)90011 -6-
mutans that has dental caries inhibiting effect (U. S. Patent
No. 4,324,782). The milk is obtained by immunizing a cow with
S. mutans antigen in two stages and obtaining the therapeutic
milk therefrom.
Stolle et al, have disclosed a method for treating
vascular disorders or pulmonary disorders associated with
smoking in an animal which comprises administering to the
animal milk collected from a cow being maintained in a
hyperimmune state (U.S. Patent No. 4,636,384). Beck has
disclosed a method for treating inflammation in an animal
which comprises administering to the animal an anti-
inflammatory effective amount of milk collected from a cow
maintained in an anti-inflammatory factor producing state
(U.S. Patent No. 4,284,623). Heinbach, U.S. Patent No.
3,128,230, has described milk containing globulins of alpha,
beta, and gamma components by inoculating a cow with antigenic
mixtures. Peterson et al. (U. S. Patent No. 3,376,198),
Tunnah e~
~1. (British Patent No. 1,211,876) and Biokema S.A. (British
Patent 1,442,283) have also described antibody-containing
milks.
None of the aforementioned references, however, disclose
the identity of the component or components of therapeutic
milks which produce the desired therapeutic effects. For
example, in Beck, U.S. Patent No. 4,284,623, the milk products
used as a therapeutic means consist of either fluid whole
milk, fluid fat-free whey, or whole milk powders. Although
each of these milk products has anti-inflammatory properties,
the factor or factors that actually provide the therapeutic
benefits have not yet been isolated or identified.
WO 92/04035 9 ~ PCT/US91 /04174
_7-
SUMMARY OF THE INVENTION
The present invention is based upon the inventors'
consideration that an isolated and purified anti-inflammatory
milk product would be most useful to treat anti-inflammatory
disorders in an animal.
With this in mind, the present inventors isolated and
partially purified and characterized an anti-inflammatory
factor from hyperirt~nune bovid milk, hereinafter called milk
anti-inflammatory factor (MAIF).
Accordingly, the present invention includes the purified
milk anti-inflammatory factor, isolated from milk from milk-
producing animals previously hyperimmunized against particular
polyvalent antigens. It is effective against inflammatory
conditions when isolated, purified, and administered in an
amount and under a regimen sufficient to produce anti-
inflammatory effects. The isolation of the active factor from
milk of hyperimmunized bovines led to the unexpected finding
that MAIF occurs in small quantities in the milk of normal
bovines. This discovery had been hidden by the fact that the
concentration of MAIF in normal bovine milk is too low to
confer discernible anti-inflammatory properties to the milk.
The MAIF of normal milk can, however, be concentrated by the
isolation process of the invention, and thereafter can be used
effectively to treat inflammation.
The present invention further includes the use of
purified MAIF as a means of blocking the cellular inflammatory
response by administering a blocking dose of hyperimmune milk
factor to an animal in which the blocking dose is sufficient
to effectively block the cellular inflammatory response. The
blocking dose is sufficient to inhibit the migration of
inflammatory cells particularly where the inflammatory cells
are neutrophils. The MAIF is also used to inhibit the
inflartanatory response that occurs during the Arthus reaction.
~ -._,.... ,
~L:i~~~~i~~
~P''~~~' 3 0 SEP
2 D ~ ~ 01 1 '1992
-8- Substitute Sheet
The MAIF can also be used to inhibit the cellular inflammatory
response that results from infection of an animal. MAIF can also
be used as a means of blocking the cellular inflammatory response
that results from acute phase reactant release. MAIF can also be
used to inhibit cytokine action in an animal by administering an
effective blocking dose of hyperimmune milk factor to the animal.
The inhibition of cytokine action above is at the receptor of an
inflammatory cell. The MAIF may also be used to prevent the
adhesion of neutrophils to endothelial cells. The use comprises
administration of a blocking dose of MAIF to an animal wherein
the blocking dose is sufficient to effectively prevent the
' adhesion. MAIF is advantageously administered intravenously.
BRIEF DESCRIPTION OF THE DRAWINGS
A more complete appreciation of the invention and many of
the attendant advantages thereof will be readily obtained as the
same becomes better understood by reference to the following
detailed description when considered in connection with the
accompanying drawings, wherein:
FIGURE 1. Isolatian of MAIF by ion-exchange chromatography
on a column of DEAE-cellulose, in Step 2 of the preferred
process.
FIGURE 2. Fractionation of the MAIF peak (second) from
DEAE-cellulose chromatography (Fig. 1) on a Sephadex G-10
molecular sieve column, in step 3 of the preferred process.
FIGURE 3. Effect of immune milk on carrageenan-induced
edema in rats (paw weight, 9G control paw, mean ~ sem, n=10).
FIGURE 4. Effect of intraperitoneal MAIF on footpad edema
in rats (girl, mean ~ SD, n=6).
FIGURE 5. Intraperitoneal dose-response curve for MAIF in
rat paw edema test (% control, mean ~ SD, n=6).
r.: .:.. , . , ,.
vvi~Ji:!.;:~ us~t~T
/FE~/US
WO 92104035 2 0 9 0 011 ~P~/US91/04174
_g_
FIGURE 6. Effect of hyperimmune milk factor (MAIF) vs.
placebo (lactose) on footpad edema in rats (% control, mean ~
SD, n=6).
FIGURE 7. Effect of iv and oral MAIF on footpad edema in
rats (% control, mean ~ SD, n=6).
FIGURE 8. Effect of low iv dosage of MAIF on footpad
edema in rats (X control, mean ~ SD, n=6).
FIGURE 9. Intravenous dose-response curve for MAIF in
rat paw edema test (% control, mean ~ SD, n=6).
FIGURE 10. Run 1, twin herd/ultrafiltration experiments
(% average control edema, mean ~ SD, n=6).
FIGURE 11. Run 2, twin herd/ultrafiltration experiments
(% average control edema, mean ~ SD, n=6).
FIGURE 12. Run 3, twin herd/ultrafiltration experiments
(% average control edema, mean ~ SD, n=6).
FIGURE 13. Effect of various treatments of MAIF on
inhibition of footpad edema in rats (~L footpad edema, mean ~
SD, n=6).
FIGURE 14. Effect of fractions of MAIF and of immune wpc
on inhibition of footpad edema in rats (pL footpad edema, mean
~ SD, n=6).
FIGURE 15. Effect of five different anesthetics on the
response to carrageenan in the rat footpad. The accumulation
of edema was monitored at selected intervals in the same
animals. n = 6 for each data point.
FIGURE 16. Demonstration of the biphasic nature of the
response to carrageenan in the rat footpad. n = 5 for each
data point. Ether was used as the anesthetic.
FIGURE 17. MAIF, administered at either 5 mg per rat (A)
or 40 mg per rat (B) does not inhibit the inflartunatory
response to carrageenan in ether-anesthetized rats. n = 4 for
all data points.
FIGURE 18. Suppression of carrageenan-induced edema
accumulation during the secondary, phagocytic-cell mediated,
WO 92/04035 PCT/US91/04174
2000011
-lo-
response by 40 mg of MAIF injected i.v. at the time of
carrageenan challenge (Mime 0). n = 12 for each data point in
the control group and n = 10 for each data point in the MAIF-
treated group.
FIGURE 19. Effect of MAIF, given i.v. at 4 mg per rat at
different times, on the response to carrageenan in the rat
footpad. Edema was assessed 4 hours after challenge in all
cases. n = 12 for each data point.
FIGURE 20. Effect of 20 mg of MAIF injected i.v. on the
reverse passive Arthus reaction. * = p < 0.01; ** = p < 0.05.
FIGURE 21. Effect of decreasing doses of MAIF on the
ability of neutrophils to emigrate from the vasculature into
subcutaneously implanted sterile sponges. * = p < 0.01.
FIGURE 22. Effect of MAIF, administered at a dose of 20
mg per rat, to inhibit the ability of inflammatory cells to
accumulate in subcutaneously implanted sponges when
administered at the time of implant or up to 120 minutes after
implant. * = p < 0.01.
FIGURE 23. Time course of the cellular inflammatory
infiltration into subcutaneously implanted sponges in normal
animals.
FIGURE 24. Effect of 40 mg of MAIF administered i.v. on
the number of circulating neutrophils and lymphocytes in the
24 hours following injection.
FIGURE 25. Dose-response relationship between i.v. MAIF
administration and circulating leukocyte numbers (p < 0.01).
FIGURE 26. Suppression of infection-induced edema by 40
mg of MAIF injected i.v. The mean values of the two groups
were: controls, 87 t 22 ~L; MAIF, 45 ~ 17 ~cL; p < 0.01.
FIGURE 27. Effect of MAIF given i.v. at 40 mg per rat on
bacterial replication and subcutaneously implanted, F. coli-
infected sponges.
FIGURE 28. Inhibition of inflammatory cell infiltration
into infected sponges by MAIF (40 mg per rat, i.v.).
_.
> > i ~~«/(;$ ~~!llJlJ .
3 0 S E P 1992
-11- Substitute Sheet
FIGURE 29. Effect of MAIF (40 mg per rat, i.v.) on
suppression of the intermediate phase (4-16 hours) of
inflammatory fluid accumulation in E. coli-infected sponges.
FIGURE 30. Effect of 40 mg of MAIF, given intravenously at
the time of challenge and 48 hours later, on the pathogenesis of
experimental pyelonephritis. The dotted line on the left-hand
graph represents the mean background kidney weight. * = p <
0.01; ** = p < 0.02.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention comprises the isolation and purification of
MAIF and the administration of said MAIF to an animal for the
purpose of treating anti-inflammatory disorders.
By the term "milk anti-inflammatory factor" is intended a
factor obtained from either hyperimmune milk or normal cow's
milk. By the term "substantially pure milk anti-inflammatory
factor" is intended, for the purpose of this invention, an anti-
inflammatory factor that elutes as a single major symmetrical
peak on HPLC chromatography, after removal of high molecular
weight substances (>10,000 daltons) and isolation of the low
molecular weight, negatively-charged species by ion-exchange
chromatography. Both normal milk and hyperimmune milk can be
processed by the methods described herein to obtain the MAIF.
By the term "hyperimmune milk" is intended, for the purpose
of this invention, milk obtained from milk-producing animals
maintained in a hyperimmune state, the details for
hyperimmunization being described in greater detail below.
By the term "whey" i s i ntended, for the purpose of thi s
invention, milk from which cream has been removed.
By the term "normal milk" is intended for the purpose of
the invention milk that is obtained from milk-producing animals
by conventional means and dairy practices.
vLIGJIi!UIt Sh~ET
IPEA~US ,
WO 92/04035 PC1'/US91 /0417a
2090011
-m-
By the term "milk-producing animal" is intended, for the
purpose of this invention, mammals that produce milk in
commercially feasible quantities, preferably cows, sheep and
goats, more preferably dairy cows of the genus os (bovid),
particularly those breeds giving the highest yields of milk,
such as Holstein.
By the term "bacterial antigen" is intended, for the
purpose of this invention, a lyophilized preparation of heat-
killed bacterial cells.
By the term "microencapsulated form" is intended, for the
purpose of this invention, polymeric microparticles
encapsulating one or more bacterial antigens for
administration to milk-producing animals.
By the term "inflammation" is intended, for the purpose
of this invention, a localized protective response elicited by
injury or destruction of tissues which serves to destroy,
dilute or wall off both the injurious agent and the injured
tissue, characterized in the acute form by the classical
sequence of pain, heat, redness, swelling, and loss of
function, and histologically involving a complex series of
events, including dilatation of the arterioles, capillaries,
and venules with increased permeability and blood flow,
exudation of fluids including plasma proteins, and leukocyte
migration into the inflammatory focus.
By the term "treating" is intended, for the purposes of
this invention, that the symptoms of the disorder and/or
pathogenic origin of the disorder be ameliorated or completely
eliminated.
By the term "administer" is intended, for the purpose of
this invention, any method of treating a subject with a
substance, such as orally, intranasally, parenterally
(intravenously, intramuscularly, or subcutaneously), or
rPCtally.
'lr ~ ~t,~~''j i ~ ~.Irir~ / '~
( ~ ~~',,; ~
2090011 30 SEP1992
-13- Substitute Sheet
By the term "animal" is intended, for the purpose of this
invention, any living creature that is subject to inflammation,
including humans, farm animals, domestic animals, or zoological
garden animals.
Examples of inflammatory conditions that may be treated by
the isolated and purified milk product of the present invention
are conditions selected from the group consisting of acute and
subacute bursitis, acute non-specific tendonitis, systemic lupus
erythematosis, systemic dermatomyositis, acute rheumatic
carditis, pemphigus, bullous dermatitis, herpeteformis, severe
erythema, multiform exfoliative dermatitis, cirrhosis, seasonal
perennial rhinitis, bronchial asthma, ectopic dermatitis, serum
sickness, keratitis, opthalmicus iritis, diffuse ureitis,
choriditis, optic neuritis, sympathetic opthalmia, symptomatic
sarcoidosis, Loeffler's syndrome, berylliosis, hemolytic anemia,
mastitis, mastoiditis, contact dermatitis, allergic
conjunctivitis, psoriatic arthritis, ankylosing spondylitis,
acute gouty arthritis, and herpes zoster. Further, the isolated
and purified milk product may be used to treat individuals wh_o
are exposed to potentially inflammatory agents.
The invention is based in part on the discovery that when
a milk-producing animal such as a bovid is brought to a specific
state of hyperimnunization, the animal will produce milk which
has supranormal levels of the highly beneficial MAIF, said MAIF
not only suppressing the symptoms of inflammation in man and
other animals, but also being a prophylactic agent in antici-
pation of the presence of inflammatory agents in the recipient.
By the term "supranormal levels" is intended levels in excess of
that found in milk from non-hyperimmunized animals. The
induction of immune sensitivity alone is insufficient to cause
the appearance of supranormal levels of MAIF in milk, as is shown
by the fact that normal cow's milk does not contain these
S~!G;;i.iUTE ShEEZ
~PEAIUS
CA 02090011 2001-08-20
WO 92/04t13~ ~ ~ ~ ~ PCT/US91/0417.t
-14-
supranormal levels, even though the cows have become
sensitized against various antigens during normal irtanunization
against cow diseases and during normal exposure to the
environment. 1t is only in specific hyperimmune states that
the milk has the desired supranormal levels.
This special state may be achieved by administering an
initial immunization, followed by periodic boosters with
sufficiently high doses of specific antigens. The preferred
dosage of booster should be equal to or greater than SOX of
the dosage necessary to produce primary immunization of the
bovid. Thus, there is a threshold boaster dosage below which
the properties are not produced in the milk, even though the
cow is in what normally would be called an immune state. In
order to achieve the requisite hyperimmune state, it is
essential to test the hyperimmune milk after a first series of
booster administrations. If the beneficial factors are not
present in the milk, additional boosters of high dosage are
administered until the properties appear in the milk.
The process of producing the hyperimmune milk containing
supranorrnal levels of MAIF is disclosed in
U.S. Patent No. 5,106,618 which issued on April 21, 1992 and
U.S. Patent No. 4,919,929 which issued on April 24, 1990.
In summary, one process o'F
producing the hyperimmune milk containing supranarmal levels
of MAIF comprises the following steps: (1) antigen selection;
(2) primary immunization of the bovid; (3) testing the serum
to confirm sensitivity induction: {4) hyperimmunization with
boosters of appropriate dosage; and, optionally, (5) testing
the milk for anti-inflammatory properties; (6) collecting the
milk from the hyperinmune bovid; and (7) processing the milk
to isolate the MAIF.
WO 92/04035 PCT/US91/04174
2090Q11
-15-
Step 1: Any antigens or combination of antigens may be
employed. The antigens can be bacterial, viral, protozoan,
fungal, cellular, or any other substances to which the immune
system of a milk-producing animal will respond. The critical
point in this step is that the antigens) must be capable, not
only of inducing immune and hyperirtanune states in the milk-
producing animal, but also of producing supranormal levels of
MAIF in the milk. Any antigen can be used to produce
supranormal levels of MAIF. One preferred vaccine is a
mixture of polyvalent bacterial antigens, referred to as
Series 100 vaccine, described in detail in Example 1A below.
Step 2: The antigens) can be administered in any method
that causes sensitization. In one method, a vaccine composed
of antigen derived from 1x106 to 1x1020, preferably 108 to
1010, most preferably 2x108, heat-killed bacteria is adminis-
tered by intramuscular injection. However, other methods such
as intravenous injection, intraperitoneal injection, rectal
suppository, or oral administration may be used.
Step 3: It is necessary to determine whether or not the
milk-producing animal has become sensitive to the antigen.
There are a number of methods known to those skilled in the
art of immunology to test for sensitivity (Methods in
Immunolo4v and Immunochemistrv, William, C.A., and Chase,
W.M., Academic Press, New York, vols. 1-5 (1975)). The
preferred method is to use a polyvalent vaccine comprising
multiple bacterial species as the antigen and to test for the
presence of agglutinating antibodies in the serum of the
animal before and after challenge with the vaccine. The
appearance of milk antibodies after immunization with the
vaccine indicates sensitivity; at this point it is possible to
proceed to step 4.
Step 4: This involves the induction and maintenance of
the hyperimmune state in the sensitized animal. This is
accomplished by repeated booster administration at fixed time
WO 9~;/0403~ PCT/US91/04174
20Q~0011
-16-
intervals of the same polyvalent vaccine that was used to
achieve the primary sensitization. A two-week booster
interval is optimal for polyvalent bacterial antigens.
However, it is necessary to ensure that the animal does not
pass from a hyperimmune state to a state of immune tolerance
to the antigen.
In a preferred embodiment, hyperimmunization of bovids
may be achieved by a single administration of
microencapsulated vaccine, prepared as described in detail in
Example 1B below. The advantage of the controlled release
form of hyperimmunizatio~n is that the constant exposure to the
antigen ensures that the animal remains in the hyperimmune
state.
In an alternative embodiment, it is also possible to
combine different immunization procedures, e.9., simul-
taneously administering microencapsulated and liquid antigen,
or intramuscular injecaion for primary immunization, and
booster doses by oral administration or parenteral
administration by microencapsulation means. Many different
combinations of primary and hyperimmunization are known to
those ski 11 ed i n the art; .
Step 5: It is necessary to test the milk for anti-
inflammatory activity levels. This can be accomplished by any
research technique that tests the effects of either the
hyperimmune milk or products derived therefrom upon
inflannnation. Chemical-induced inflammation of the rat paw is
a standard assay for anti-inflammatory drugs.
Step 6: This involves the collection and processing of
the milk. The milk can be collected by conventional methods.
Processing the milk to 'isolate the MAIF is described below.
The simplest process for isolating, purifying and testing
the MAIF comprises the ~~Following steps:
I. defatting the hyperimmune milk to produce skim milk;
2. removing casein from skim milk to produce whey;
CA 02090011 2001-08-20
.rrT,..~=,~ ~~~ 7 ~
209001 1 ' 'f~' _
IP~A/US 3 ~ SEP1992
-1~- Substitute Sheet
3. removal from the whey macromolecules of molecular
weight greater than about 10,000 daltons by ultrafiltration;
4. fractionating the product from step 3 using an ion-
exchange resin column to isolate a negatively-charged MAIF
species of molecular weight less than about 10,000 daltons;
5. separating the negatively-charged species from step
4 by molecular sieve chromatography; and
6. biological assay of MAIF from step 5.
In an alternative preferred embodiment, the fractions
from molecular sieve chromatography that have biological
activity are further purified by filtration through a membrane
that retains macromolecules of molecular weight greater than
about 5000 daltons.
7. The anti-inflartmatory action of the milk factor is
tested on edema that is caused by the injection of a solution
of carrageenan into the paw of rats. The rat paw test is the
standard animal test for anti-inflammatory drugs. Winter,
C.A., Risley, G.A., Nuss, A.W., "Carrageenan-Induced Edema in
the Hind Paw of the Rat as an Assay for Anti-inflammatory
Orugs," Proc. Soc. Exp~er. Biol. Med. x:544 (1967). A variety of
other tests may be used. Wetnick, A.S., and Sabin, C.,
"The Effects of Clonixin and Bethaurethasone on Adjuvant-
Induced Arthritis and Experimental Allergic Encephalomyelitis
in Rats,' Jao. J. Pharm. x:741 (1972). However, the rat paw
test is the most simple and direct test available, and has been
shown to be satisfactory for all anti-inflammatory drugs. This
test has been described in detail in Beck, U.S. Patent 4,284,623,
Briefly, the test involves the
injection of a small quantity of carrageenan into the footpad of
adult white rats. This is known to induce an inflartmatory
response. The resulting degree of swelling can be quantified.
Samples containing anti-inflammatory factor are administered to
the rat by a suitable route, preferably by intraperitoneal
vJuJii~i~TE SHEET
lFEA/US
WO 92/04035 PCT/US91/04174
2090011
-18-
injection, and the blockade or amelioration of the
inflammatory process quantified by either volumetric or
gravimetric methods.
In sunmary, one can isolate the anti-inflartmatory factor
from hyperimmunized milk by following a process of defatting
the milk, removing casein, removing macromolecules of greater
than 10,000 daltons, and continuing with ion exchange and
molecular sieve chromatography. The biological activity of
appropriate preparations of anti-inflammatory factor can be
tested by doing a dose-response experiment on rats as
described herein.
The compositions of the present invention may be
administered by any means that provide anti-inflammatory
activity. For example, administration may be parenteral,
subcutaneous, intravenous, intramuscular, intraperitoneal or
oral.
Solid dosage forms for oral administration include
capsules, tablets, pills, powders and granules. In such solid
dosage forms the active compound is admixed with at least one
inert diluent such as sucrose, lactose or starch. Such
dosage forms can also comprise, as is normal practice,
additional substances other than inert diluent. In the case
of capsules, tablets, and pills, the dosage forms may also
comprise buffering agents. Tablets and pills can additionally
be prepared with an enteric coating.
Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsion, solutions, suspensions,
syrups and elixirs containing inert diluents commonly used in
the pharmaceutical art. Besides inert diluents, such
compositions can also include adjuvants, such as wetting
agents, emulsifying and suspending agents, and sweetening.
Preparations according to this invention for parenteral
administration include sterile aqueous or nonaqueous
solutions, suspensions or emulsions. Examples of nonaqueous
~~~7~~~~~~Q4
209001:1 . . .. ~; .~ ~ ,,y2
-19- Substitute Sheet
solvents or vehicles are propylene glycol, polyethylene glycol,
vegetable oils such as olive oil and injectable organic esters
such as ethyl oleate.
The dosage of active ingredients in the composition of this
invention may be varied; however it is necessary that the amount
of the active ingredient shall be such that a suitable dosage
form is obtained. The selected dosage form depends upon the
desired therapeutic effect, on the route of the administration
and on the duration of the treatment.
Administration dosage and frequency will depend on the age
and general health condition of the patient, taking into
K
consideration the possibility of side effects. Administration
will also be dependent on concurrent treatment with other drugs
and patients tolerance of the administered drug.
The invention is based in part upon the unexpected
discovery that a MAIF can be isolated and purified and is
effective in treating a variety of inflammatory processes in
humans and animals. In a preferred embodiment, the MAIF is
produced by hyperimmunizing a milk-producing animal against a
bacterial antigen vaccine. The vaccine used to hyperimnunize the
animals does not contain anti-inflammatory activity. It is
surprising, therefore, that treatment with an isolated and
purified factor, obtained from animals immunized against a mixed
bacterial antigen vaccine, is effective in alleviating or
eliminating inflammatory processes.
Having now described the invention in general terms, the
same will be further described by reference to certain specific
examples that are provided herein for purposes of explanation
only, and are not intended to be limiting unless otherwise
specified.
;.:~~~iIiUTE SHEE'(
iPEA/US
WO 92/04035 PCT/US91/04174
2090011
2 ,~
-20-
Example 1A
Preparation of S-100 Vaccine
A bacterial culture containing the spectrum of bacteria
shown in Table 1 below as obtained from the American Type
Culture Collection was reconstituted with 15 ml of media and
incubated overnight at ~7'C. Once good growth was obtained,
approximately one-half of the bacterial suspension was
employed to inoculate one liter of broth with the inoculate
being incubated at 37"C. The remaining suspension was
transferred to sterile glycol tubes and stored at -20'C for up
to six months.
After good growth was visible in the culture, the
bacterial cells were harvested by centrifugation of the
suspension for 20 minutes to remove the media. The bacterial
pellet obtained was resuspended in sterile saline solution and
the bacterial sample was centrifuged three times to wash the
media from the cells. After the third sterile saline wash,
the bacterial pellet obtained upon centrifugation was
resuspended in a small amount of double distilled water.
The media-free bacterial suspension was heat-killed by
placing the suspension in a glass flask in an 80'C water bath
overnight. The viability of the broth culture was tested with
a small amount of heat-gilled bacteria. Broth was inoculated
with heat-killed bacteria, incubated at 37'C for five days and
checked daily for growth, as the bacteria have to be killed
for use in the vaccine.
The heat-killed bacteria were lyophilized until dry. The
dry bacteria were then mixed with sterile saline solution to a
concentration of 2.2 x 108 bacterial cells/ml saline (1.0
optical density reading at 660 nm).
.s
~p~~~~ r ~ ~~5~ i / fl417 4
3 0 S EP1992
2090011
-21- Substitute Sheet
Table 1
S-100 Bacteria List
Gram
Name Media + or - ATTC #
1. Staph. aureus BHI + 11631
2. Staph. epidermidis BHI + 155
3. Strep. pyogenes, A. 1 APT + 8671
Type
4. Strep. pyogenes, A. 3 APT + 10389
Type
5. Strep. pyogenes, A. 5 APT + 12347
Type
6. Strep. pyogenes, A. 8 APT + 12349
Type
7. Strep. pyogenes, A. 12 APT + 11434
Type
8. Strep. pyogenes, A. 14 APT + 12972
Type
9. Strep. pyogenes, A. 18 APT + 12357
Type
10. Strep. pyogenes, A. 22 APT + 10403
Type
11. Aerobacter aerogenes BHI - 884
12. Escherichia coli BHI - 26
13. Salmonella enteritidis BHI - 13076
14. Pseudomonas aeruginosa BHI - 7700
15. Klebsiella pneumoniae BHI - 9590
16. Salmonella typhimurium BHI - 13311
17. Haemophilus influenzae BHI - 9333
18. Strep. mitis BHI + 6249
19. Proteus vulgaris BHI - 13315
-
20. Shigella dysenteriae BHI - 11835
21. Diplococcus pneumoniae APT + 6303
22. Propionibacter aches Broth + 11827
23. Strep. sanguis APT + 10556
24. Strep. salivarius APT + 13419
25. Strep. awtans BHI + 25175
26. Strep. agalactiae APT + 13813
Cows were given daily injections of 5 ml samples of the
polyvalent liquid vaccine. Antibody (IgG) titer levels for the
injected cattle were determined periodically by using an enzyme-
linked immunoassay for bovine antibody against the polyvalent
antigen.
.''.a~~Si.r~'TF ~~iFET
'fl.Cp ,-yn
CA 02090011 2001-08-20
WO 92/04036 ~ ~ ~ ~ PCT/LJS91 /0417a
_22_
Example 1B
Immunization Procedures
Heat-killed bacteria were prepared in the manner
described above. The polyvalent antigen sample (S-100)
obtained was microencapsulated by a conventional phase-
separation process to prepare a polyvalent antigen-containing
microparticle product. Generally, the antigen-containing
shaped matrix materials are formed from polymers of biocom-
patible material, preferably biodegradable or bioerodable
materials, preferably polylactic acid, polyglycolic acid,
copolymers of lactic and glycolic acids, polycaptolactone,
copolyoxalates, proteins such as collagen, fatty acid esters
of glycerol, and cellulose esters. These polymers are well
known in the art and are described, for example, in U.S.
3,773,919; U.S. 3,887,699; U.S. 4,118,470; U.S. 4,076,798.
The polymeric matrix
material employed was a biodegradable lactide-glycolide
copolymer.
Heat-killed bacterial antigens are encapsulated in such
matrix materials, preferably as microspheres of between 1-500
microns diameter, preferably 10-250 microns. The
encapsulation processes are conventional and comprise phase
separation methods, interfacial reactions, and physical
methods. Many combinations of matrices and many
concentrations of assorted antigens may be employed, in order
to provide for optimal rates of release of bacterial antigens
to the host body from the microparticles. These combinations
can be determined by those skilled in the art without undue
experimentation.
The microparticles in the example were less than 250
microns in diameter. Approximately 750 mg of microparticles
containing 22K (16.5 mg) of polyvalent antigen was then
CA 02090011 2001-08-20
WO 92104035 2 0 9 ~ ~ ~ 1 PCT/l.'S91 /041 ii
-23-
suspended in about 3 cc of a vehicle (1 wt 9e Tween 20 and 2 wt
X carboxymethyl cellulose in water).
A smal 1 group of cattl a was sel ected from a 1 arger herd
of cattle. Five of these randomly selected cattle were
selected as controls. Four cattle were injected
intramuscularly with microparticles containing polyvalent
anigen. Microparticle samples were sterilized with 2.0 mRad
of gamma radiation. Antibody (IgG) titer levels were deter-
mined periodically from samples of cows' milk obtained from
the inoculated cows, as well as from the control cows.
Example 2
Tsolation of MAIF Factor from Hv~erimmunized Milk
Step 1: Milk Filtrate Preoaration
Twenty liters of fresh milk from hyperimmunized cows were
run through a cream separator (DeLaval* Model 102) to remove
the fat.
The resulting sixteen liters of skimmed milk was ultra-
filtered to remove the high molecular weight species (over
10,000 daltons) using a hollow fiber
diafiltration/concentrator (Amicon DL-lOL). The concentrator
is equipped with two 10,000 daltons molecular weight cut-off
cartridges (Amicon H5P10-43)* The skimmed milk was run at the
pump speed of 80 on the meter and inlet and outlet pressure of
30 psi and 25 respectively.
Twelve liters of the filtrate (<10,000 daltons) coming
out of the cartridges at the flow rate of four liters per hour
was frozen or lyophilized for storage and for further
purification.
Step 2: jQn-Exchange Chromatoaraohv
The milk anti-inflammatory factor, MAIF, in the filtrate
was first isolated by an anion exchange chromatography column.
* Trademark
CA 02090011 2001-08-20
WO 92/04035 PCT/L'S91/04174
_24_
2090011
In this procedure, DEAE-Sepharose CL-6B gel (Pharmacia)
was used to pack a SxlOcm glass column which was equilibrated
with sterile double distilled water, pH 7Ø
One liter of filtrate (<10,000) was applied to the column
and eluted with sterile double distilled water, pH 7.0 at the
flow rate of 160m1 per hour. Ten milliliter fractions were
collected and monitored at 280nm in an LKB Uvicord 4700
absorptiometer with an optical density printed out on a
connected recorder (Pharmacia REC-482).
The substances other than MAIF having positive and
neutral charges are not bound to the DEAE-Sepharose gel. They
are eluted at the fallthrough peak (first peak). The MAIF
carrying a negative charge is retained by the gel.
To discharge the MAIF, the column was eluted with a
stepwise gradient using sterile physiological saline, pH 7Ø
A typical profile is shown in Figure 1. Bioassay of the
individual fractions revealed that the second peak contains
the MAIF. Fractions comprising the second peak and its
shoulder are used for further purification. Recovery studies
show that 8.8 grams of dried powder were obtained by this
process.
Step 3: Gel Filtration Chromatograohv
The second peak obtained from Step 2 contains MAIF and
other negatively charged molecules; therefore, an additional
refining step was needed. To achieve further purification, it
is convenient to use a gel filtration column to separate
various components on the basis of molecular weight.
In this process, Sephadex G-10 resin (Pharmacia) was
packed into a 2.5x80cm glass column and equilibrated with
sterile double distilled water, pH 7Ø Two grams of the
second fraction from Step 2 was redissolved in sterile double
distilled water and applied to the top of the column. The
column was eluted at the flaw rate of 30m1 per hour.
*Trademark
WO 92,04035 PCT/US91 /0417.
~(~~OU11
-25-
Fract i ons (3 .3 ml ) were col 1 ected and mon i tored at 254nm and
280nm (Pharmacia Duo Optical Unit) with optical density
printed out on a connected recorder (Pharmacia REC-482).
Typically, there were 3 peaks shown in the elution
profile as illustrated in Figure 2. The first and second
peaks contained MAIF activity.
The first peak is an aggregate that forms on the G-10
column which contains the active MAIF.
The second peak contains the nonaggregated form of the
MAIF. Both the aggregate form (peak 1) and the nonaggregated
form (peak 2) are biologically active in rat bioassay.
Example 3
Characterization of Milk Anti-inflammatory Factor
The molecular weight of the non-aggregated form of MAIF
prepared by the method described above was found to be less
than 10,000 daltons. This was deduced from the fact that the
first step in the isolation of MAIF from whey was by
ultrafiltration using a membrane that does not allow the
passage of molecular weight species >10,000 daltons.
The MAIF has a negative charge. This was determined by
applying milk ultrafilgrate to a DEAE cellulose ion exchange
column. The MAIF did not elute from the column with water.
Changing the elution media to sodium chloride (0.9% pH) caused
the elution of several peaks (Fig. 1). Neutral and positive
charged species do not adhere to the ion exchange resin, and
negative charged species are eluted by increasing the salt
concentration. When t:he less than 10,000 dalton molecular
weight permeate was applied to the DEAE column, neutral salts
and sugars eluted with water (Peak 1, Fig. 1). Three distinct
peaks eluted when the buffer was changed to saline (Peaks 2-
4). The second peak and its shoulder contained MAIF
WO 9/0403 PCT/US91 /04174
~pgppl~
-26-
biological activity in the rat assay. It is concluded,
therefore, that the MAIF has a negative charge.
Another chemical characteristic of the MAIF is that it
forms an aggregate during the process of removing salt. This
property becomes apparent when <10,000 dalton molecular weight
permeate was passed over a Sephadex G-10 column, equilibrated
with double distilled water and eluted with water at a pH of 7
(Fig. 2). Three peaks eluted from the G-10 column; the first
peak eluted with the void volume suggesting a molecular weight
equal to or greater than 10,000 dalton. This was unexpected
because molecules greai:er than 10,000 daltons had previously
been removed from this sample by ultrafiltration. The second
peak eluted in the position expected for the anti-
inflammatory factor. Both the first and second peaks
exhibited anti-inflammatory biological activity in the rat paw
assay, whereas the third peak lacked activity. It was
surprising to find that both the first and second peaks had
anti-inflartanatory biological activity. The material recovered
from the first peak of the G-10 column (Step 3) was lyophili-
zed and applied to a G-100 column; a single peak was eluted
with the void volume, suggesting a molecular weight of 100,000
daltons or greater. fhe Step 3 G-10 column removes salt at
the same time it separates the different molecular weight
species. It is concluded, therefore, that during passage over
the G-10 column and resulting removal of salt the anti-
inflammatory factor formed a large molecular weight aggregate.
The degree of aggregation varied with the salt concentration.
The aggregation property suggests the possibility that a
wide spectrum of different molecular weight species can be
formed which have anti-inflammatory biological activity due to
the presence of the anti-inflammatory factor. The discovery
of this property suggests the possibility of producing milk
anti-inflammatory factors having a wide spectrum of different
biochemical properties depending on the degree of aggregation
WO 92/04035 2 0 9 0 011 p[T/US91/04174
_27_
of the final product. For example, formulations having longer
or shorter biological half lives might be produced by using
larger or smaller molecular weight aggregates, with molecular
weight distribution being controlled by the salt concentration
during processing. The column chromatography method described
herein results in the smallest molecular weight species that
has been obtained which has biological activity (i.e., peak 2
from the Step 3 G-10 co'lumn). This observation also suggests
using other methods for forming the aggregates. For example,
dilution in water causes the aggregation to occur. Chemical
agents that bind salts;, especially calcium, can cause the
formation of the aggregate. Having made this discovery, other
methods for forming the aggregate and separating the MAIF will
be obvious to those skilled in the art.
Example 4
Biological Activity Assay
The anti-inflammatory action of the MAIF was tested on
edema that was caused by the injection of a solution of
carrageenan into the footpads of rats. A lyophilized sample
of the MAIF was dissolved in the appropriate vehicle and given
intraperitoneally to experimental rats. The carrageenan was
then administered to the rats in an amount of 0.1 ml of a 1%
saline solution in each hind footpad. The footpads were
measured before injections were given and 2.5 hours after the
injections, using a thickness gauge. The results are
illustrated in Tables 2 and 3.
The non-aggregated form of MAIF (peak 2 from the G-10
column) from control and hyperimmune milk caused reduction in
inflammation of the rat paw at doses between 1 mg and 0.25 mg
(Table 2). Both the hyperimmune milk and the regular milk
exhibited activity; however, the hyperimmune material was more
PCT/ US91 /04174
'7~(10~ ~' ~1 ~S
2090011
-28-
potent. We concluded from this that the MAIF occurs in
greater concentration i~n the milk from hyperimmune cows.
The second peak ferom the DEAE column exhibited activity
when isolated from either hyperimmune milk or regular milk.
The activity is substantially greater in the hyperirtmune milk
(Table 3).
The first peak from the G-10 column, which is the
aggregated form of MAII=, exhibited activity in rat paw tests
(Table 2}. However, the aggregated is not as potent as the
nonaggregated form on equal weight basis.
It is concluded from these studies that the MAIF factor
occurs naturally in cows milk. Hyperimmunization of the cows
causes higher concentration of MAIF in the milk. The MAIF is
a small, negatively charged molecule that can be separated
from the mi 1 k by a vari ety of methods . The MAIF factor can
form large molecular weight aggregates that do not naturally
occur in milk, but form during processing.
WO 92/04035 ~ D 9 0 011 P~/US91 /0417a
_29_
TABLE 2
EFFECT OF MILK ANTI-INFLAMMATORY FACTOR (MAIF)
ON REDUCTION OF INFLAMMATION IN RATS
DOSAGE Before After Inflam
Iniection ln~ection Difference mation
2.0 mg/
rat 3.43 5.01 1.58 46
1.0 mg/
rat 3.49 5.39 1.90 54
0.5 mg/
rat 3.42 5.51 2.09 61
0.1 mg/
rat 3.43 5.86 2.43 71
Control/
Saline 3.43 5.82 2.39 70
Prepaired from NormalCows Milk
2.0 mg/
rat 3.30 5.24 1.94 59
1.0 mg/
rat 3.31 5.22 1.91 58
0.5 mg/
rat 3.32 5.33 2.01 61
0.25 mg/
rat 3.31 5.42 2.11 64
WO 92/04035 PCT/1JS91/04174
-30-
209001a~
TABLE 3
COMPARISON OF SEMIfURIFIED FRACTIONS OF MAIF ON
REDUCTION OF INFLAMMATION IN RATS
(Prepared From Hyperimmune and Regular Milk)
Foot Pad Measurements (mm)
2.5 hr. X
Before After Inflam-
Iniection In.iection Difference mation
DEAE Column
Second Peak
Hyperimmune
Milk
2 mg/rat 3.25 5.04 1.79 55
DEAE Column
Second Peak
Regular Milk
2 mg/rat 3.30 5.24 1.94 59
G-10 Column
First Peak
2 mg/rat 3.31 4.98 1.67 50
Control/
Saline 3.34 5.63 2.29 69
WO 92104035 PCT/US91 /0417~t
~~1~~U11
-31-
Example 5
Chemical Analysis of Anti-inflammatory Factor
Anti-inflammatory factor samples were analyzed
chemically. MAIF is not crystalline in structure, as
determined by X-ray diffraction studies. MAIF preparations
gave elemental analysis consistent with carbohydrate
composition. The C, H, 0 ratios were consistent with a
polymeric or oligomeric material with some carbinol groups
being oxidized to carboxyl. The slight excess of calcium
equivalents over chloride ions may be accounted for in part as
carboxylate salts. The remainder may be sodium or potassium
salts. However, the melting behavior, or rather the non-
melting behavior, was suggestive of salt-like and/or higher
molecular weight compositions. The material in the present
state of purity apparently contains a variable amount of salts
of calcium and chloride, probably CaClp.
Neither preparation contained a significant amount of
nitrogen which precludes any peptide component in its
composition. Likewise, the absence of significant nitrogen
can rule out the presence of amino sugars and other nitrogen-
containing materials such as various complex lipids as the
major component(s).
Pyrolytic mass spectra revealed significant traces of 18-
carbon fatty acids. This fact, taken together with traces of
N and P, suggest the presence of a complex lipid in the
factor.
Infrared spectroscopy revealed absorptions consistent
with carbinol and carboxylate functionalities. Ultraviolet,
visible and fluorescent spectroscopy revealed no significant
amount of chromophores beyond those indicated by infrared.
The chemical tests are consistent with an oligomeric
carbohydrate, wherein the carbonyl function (aldehyde or
ketone) is tied up in the subunit linkages. The oligomeric
WO 92/0403 PC1'/US91 /04174
2pppp1l
-32-
carbohydrate also contains some side-chain oxidation to
carboxylate.
The MAIF preparation is substantially, but not completely
pure.
Example 6
Rat Paw Edema Tests: Oral Administration
The rat carrageenan footpad assay was used to test the
effectiveness of MAIF as an in vivo anti-inflammatory agent.
Thirty adult white ral:s were randomly divided into three
groups of ten rats per group. The groups received, in five
consecutive daily treatments, either 10 mg of skim milk powder
from hyperimmunized animals, 10 mg of skim milk powder from
non-immunized animals or no treatment (20 ml water per day
only). The powders were orally administered in 20 ml of
water. On the fifth day the right paw of each rat was
injected with 0.1 ml of 1% carrageenan in saline. This
procedure is known to~ cause acute inflammation (edema).
Twenty-four hours after injection, the rats were sacrificed,
the paws amputated, and the weights of the left (control) and
right (edematous) paws were compared. The results of the
assay are shown in Tab 1e 4 (expressed as weight in grams) and
in Figure 3 (expressed as a percentage of the average weight
of control paws).
Table 4: Rat Paw Edema Test Results
(Paw wt, g, mean ~ sem, n=10)
CarrageenanControl Oiffer-
Treatment Paw (wt, Paw (wt, ence (a1
g1 al
Immune Milk 1.78 + 0..031.71 + 0.02 0.06 + 0.02
Control Milk1.88 + 0..061.64 + 0.03 0.24 + 0.05
Water 1.86 + 0..031.65 + 0.03 0.22 + 0.02
WO 92/04035 i PC1'/US91/04174
-33-
The inflammatory response to carrageenan injection was
markedly reduced in the immune milk treated rats as compared
with the nonimnune milk .and water control groups. No evidence
of side effects or adverse effects on the general health of
the rats was detected. From these data it can be concluded
that daily consumption of skim milk powder from hyperimmunized
animals almost completely blocked the inflammatory response
induced by carrageenan injection in the footpad of rats.
Example 7
Quantitative Rat Paw Edema Tests
A series of experiments was conducted on the hyperirtunune
milk fraction. The experiments were designed to confirm the
anti-inflammatory activity of MAIF when given
intraperitoneally and ito establish a dose response curve,
explore alternative roui:es of administration, and investigate
dosage regimens which might form the basis of further
investigations.
Peak I from the (~-10 column, supplied by Stolle Milk
Biologics International, was prepared according to the methods
described in Patent No. 4,956,349. Lactose, obtained from
commercial sources, was used as placebo. Aspirin was used as
a positive control. Aspirin was dissolved in water and given
orally by gastric gavage at the ratio of 200 mg per kilogram,
a dose known to be active in the assay. A 2% solution of
kappa carreegenan (Sigma C-1263) has been found to produce the
most reproducible results and was thus used in these
experiments. The footpad assay was modified by using
isotopically labeled human serum albumin (I25I-HSA) that
localizes in the carrageenan-induced lesion in direct
proportion to the volume of the exudate. By determining the
total radioactive count in the footpad and comparing this to
the counts in a known volume of plasma from the injected
WO 92,/04035 PCT/LJS91/04174
2pppp1l
-34-
animal, a direct measurement of edema in microliters of plasma
equivalents is obtained. 1251-HSA was injected intravenously
at a dose of 1.0 microcurie per rat. Female Dark Agouti rats
were used. The rats we're approximately 12 weeks old, weighed
between 160 grams and 200 grams, and were obtained from the
in-house inbred colony.
To conduct the carrageenan footpad assay, 0.1 ml of 2%
carrageenan was injected subcutaneously into each hind foot
pad of an anesthetized rat. This injection was followed
immediately by injection of 1.0 microcurie of 1251-HSA in 0.5
ml of saline into the i;ail vein. After four hours, each rat
was weighed, blood samples obtained, and the rat euthanized.
Both hind feet were then removed and the levels of
radioactivity in each foot and in the 200 ~1 plasma standard
were measured in an automated gamma counter. From these
measurements the volume of edema in each foot was calculated
and expressed in microliters.
Exueriment 1: Intraoeritoneal Dose Response.
Figure 4 illustrates the effect of intraperitoneal
administration of MAIF compared to lactose (CON), aspirin, and
no treatment (No Rx). i411 treatments (lactose, aspirin, MAIF)
were given 30 minutes p~~rior to the injection of carrageenan.
Carrageenan injection resulted in edema averaging 250 ~1
(No Rx). The edema was inhibited by aspirin and all dosages
of MAIF but was not inhibited by lactose. The intraperitoneal
MAIF dose-response curve, derived by expressing the data as
percentage of average control (no treatment) edema is shown in
Figure 5.
Experiment 2: Effects of Various Routes of MAIF
Administration.
Figure 6 illustrates the effect, on footpad edema, of the
administration of lactose and MAIF orally (ORAL),
intramuscularly (IM), subcutaneously (SUB Q), and
WO 92/04035 ~ p ~ ~ ~ 11 PCT/1JS91/04x 74
-35-
intraveneously (IV). Also shown are a positive control
(aspirin) and a nontreated control (NO Rx).
The preparations were administered prior to carageenan
challenge according to the following schedule: Aspirin:
orally, 30 minutes pria~r; Subcutaneous MAIF: 1 hour prior;
Oral MAIF: 24, 16 and 1 hour prior; intramuscular MAIF: 30
minutes prior; intraveneous MAIF: at the time of challenge
(isotope was also injected).
The results indicate that, expressed as the percentage of
average control edema in each separate assay, MAIF, by all
routes of administration, inhibited edema formation. Forty
milligrams of MAIF given intraveneously almost completely
abrogated the inflammatory response to carrageenan. These
results demonstrate them anti-inflammatory activity of MAIF
and, in view of the results of Experiment 1 above, suggest
that the order of effectiveness for different routes of MAIF
is IV > IP > IM > SUB Q > ORAL.
Experiment 3: Effect on Edema of Intravenous and
Extended Oral Administration: Dose Response.
Figure 7 shows the effects of IV and oral MAIF
administration on footpad edema in rats. MAIF oral treatment
(40 mg per rat per day) was given daily for six days and also
one hour before carrageenan challenge (PO). Intravenous
treatments (5, 10, 20 mg) were given at the time of
carrageenan challenge (1.V). Also shown are a positive control
(aspirin) and a negatives control (no treatment).
The results shown in Figure 7 indicate that all three
MAIF dosages result in anti-inflammatory activity that exceeds
even the activity of aspirin in the assay, whereas extended
oral administration results in marked but limited activity.
The study was therefore extended to examine the effects
of further reduced intravenous dosages of MAIF. Intravenous
dosages of lactose placebo were included as a control. The
results of these studies are shown in Figure 8. Intravenous
WO 9;/04035 PCT/US91 /04174
2090U1~-
-36-
dosages of 2.5 and 1 mg MAIF (IV) induced anti-inflammatory
activity in the range of the activity induced by aspirin. 10
ml of intravenous lactose placebo (10 mg PLAC IY) did not
induce activity in that range.
An intravenous dose response curve was derived by
combining the results of Experiments 2 and 3 and expressing
these results as percentage average control edema (no
treatment) in each separate assay. The curve is shown in
Figure 9.
The conclusions that may be drawn from the quantitative
rat paw edema tests are as follows: milk fraction peak I from
the G-10 column, extracted and purified as described in Patent
No. 4,956,349, consistently shows anti-inflammatory activity
when tested in the rat paw edema model. A dosage of 4 mgs
MAIF per rat given intravenously at the time of carrageenan
injection is sufficient. to drastically inhibit edema and was
therefore chosen as a standard against which other
preparations would be compared in further experiments.
Example 8
Anti-Inflammatory Properties of Preparations
of Hvperimmune Milk Obtained from Identical Twin Cows
The effect of vaccination on the anti-inflammatory
activity of milk was investigated by testing the bioactivity
of various milk fractions obtained from identical twin cows.
Based on the extraction methods described in Patent No.
4,956,349, an extraction scheme utilizing ultra-filtration
was devised. The processing sequence was as follows:
WO 92,04035 PCT/US91 /04174
2090~1~.
-37-
raw milk
skim
pasteurize
rennet -->
--> casein (discard)
whey
ultrafiltration --> retentate (R1)
permeate (P1)
dilute 1:4
ultrafiltration --> permeate (P2)
retentate (R2)
Milk samples were prepared from immunized twin cows, non-
immunized control twin cows, and reconstituted skim milk
powder previously prepared from immunized caws. The sample
group consisted of 45 sets of identical twin cows. One cow of
each twin set was vaccinated bi-weekly with Stolle S100 mixed
bacterin (described in Patent No. 4,956,349). The
bioactivity of the various fractions was tested by intravenous
injection using the ra,t carageenan footpad assay described
above.
The hypotheses to be tested were that
(a) hyperimmunization was responsible for the anti-
inflammatory activity described above. (b) MAIF could be
extracted on a commercial scale by ultra-filtration, and
(c) dilution of the permeate would cause aggregation of the
anti-inflammatory factor, causing it to be retained by the
30,000 molecular weight ultra-filtration membrane.
Figure 10 illustrates the results of a twin herd ultra-
filtration experiment designed to test the bioactivity of
various fractions made from the milk of non-vaccinated control
CA 02090011 1998-08-11
-38-
twins and from reconstituted milk powder from immunized cows.
The fractions that were tested are as follows: Peak I, G-10
column preparation, 4 mls (OHIO MAIF STD); RZ final retentate
from non-vaccinated twin (CONTROL TWIN R2); P2 final permeate
from the reconsti tuted mi 1 k powder (RECON 5100 P2) ; di alyzed
R2 final retentate from non-vaccinated twin (CON DIALYZED R2);
dialyzed final retentate from the reconstituted milk powder
(SI00 DIALYZED R2).
No anti-inflammatory activity could be detected in the R2
final retentate fraction prepared from nonimmunized cows, even
after dialysis. No anti-inflammatory activity was detected in
the final permeate P2 fraction prepared from the reconstituted
milk powder. The reconstituted milk powder retentate R2
fraction, following dialysis, exhibited anti-inflammatory
activity in the range of the activity of the MAIF standard.
Fig~.:re 1I illustrates the results of twin herd ultra-
filtration experiments designed to test the bioactivity of
various milk fractions made from vaccinated and nonvaccinated
twin cows and from reconstituted milk powder from immunized
cows. The fractions that were tested are as follows: Peak I,
G-10 column preparation, 4 ml (OHIO MAIF STD); dialyzed final
retentate R2 from non-vaccinated twins (CON DIALYZED RZ);
final retentate R2 from the reconstituted milk powder (RECON
S100 R2); the final retentate R2 from vaccinated twins (IMMUNE
TWIN R2); first retentate RI from the reconstituted milk
powder, diluted 4 : 1 (5100 DILUTED R1).
Little ant i-inflammatory activity was detected in the
dialyzed retentate RZ from non-vaccinated control twins or in
the non-dialyzed retentate R2 from the vaccinated twins. Some
activity is detectable by scattergram. R2 retentate prepared
without dialysis from reconstituted Stolle milk powder from
immunized cows was strongly anti-inflammatory. However, the
preparation made by dilution of the reconstituted milk before
ultrafiltration rather than dilution of whey made from the
WO 92/04035 2 Q 9 0 U 11 P~/US91/04174
-39-
milk was only marginally active. This result indicates that
anti-inflammatory activity is more efficiently extracted from
the whey fraction.
Figure 12 illust:rates the results of twin herd
ultrafiltration experiments designed to test the bioactivity
of dialyzed retentate from vaccinated twin cows. The
fractions tested are as follows: Peak I, G-10 column
preparation (OHIO MAIF STD); dialyzed final retentate R2 from
vaccinated twins (IMM DIALYZED R2); dialyzed final retentate
from the G-10 preparation (DIALYZED OHIO MAIF). The results
show that anti-inflammatory activity was present in the R2
fraction from the immunized twin after dialysis. Dialyzed
MAIF was more active in the assay than the nondialyzed MAIF
standard. This result suggests that dialysis is an effective
means of further concentrating the milk factor responsible for
anti-inflammatory activity.
The results presented in Figures 10-12 above support the
following conclusions: (1) anti-inflammatory activity can be
extracted from reconstituted milk from immunized cows by
ultrafiltration of the diluted permeate. (2) anti-
inflammatory activity was not demonstrated in the above-
preparations that were made from the milk of non-immunized
cows. (3) anti-inflammatory activity was demonstrated in the
final retentate R2 after ultrafiltration of diluted permeate
prepared from the milk: of immunized cows, but dialysis was
necessary in order to demonstrate the activity.
Example 9
Sta ilitv of MAIF, Heatin4,
and Proteinase Treatment of MAIF
The previous evidence that the milk anti-inflammatory
factor was chemically not a protein or a peptide was based
largely on chemical .analysis that consistently showed an
WO 92/04035 PCT/US91/04174
20~~0~~-
-40-
almost complete absence of nitrogen. For further
characterization of MAIF, several preparations were tested in
the rat paw edema assay, using 4 mgs of peak I, G-10 column
preparation, intravenously as the standard. The following
treatments of MAIF were done: proteinase (pronase) treatment
for six hours; six hours no proteinase treatment control;
untreated positive control; heating at 100'C for 30 minutes.
The results of this assay are illustrated in Figure 13.
The conclusions derived from this study were that the anti-
inflammatory activity is not due to a protein or peptide and
that MAIF is not inactivated by boiling. The effectiveness of
pronase treatment was verified by the finding that parallel
pronase treatment completely denatured milk protein.
Example 10
Anti-Inflammatory Activity of Further Purified
MAIF and Whev Protein Concentrate from Immunized Cows
Retentate and permeate from ultrafiltration using an
Amicon YM5 membrane werE~ tested for biological activity using
intravenous administratiion in the rat paw edema assay. In
this process, the MAIF of peak I of the G-10 column, prepared
according to Patent No.. 4,956,349, was further purified by
ultrafiltration on an Amicon YM5 membrane. This membrane
retains molecules of 5000 molecular weight or greater. Whey
protein concentrates (WPCs) were also prepared from milk from
immunized animals and fiiltered through the YM5 membrane. The
following samples were i:ested in the assay using 4 mg peak I,
G-10 column preparatian, intravenously as the standard:
permeate from Amicon YM5 ultrafiltration; retentate from
Amicon YM5 ultrafiltration; WPC from immunized cows, 30 mgs
per rat; WPC from commercial production (non-immunized cows),
30 mg per rat.
WO 92/04035 PCT/US91/04174
X490011
-41-
The results of this assay are illustrated in Figure 14.
It is clear from these results that all of the activity is in
the retentate which comprised approximately 0.5% of the total
weight of the fraction applied to the YM5 filter. The
reduction of edema seen in this experiment was achieved
following administration of 20-25 micrograms of material.
Regarding the activity of WPC, WPC made from
hyperimmunized animals clearly showed anti-inflartmatory
activity as expected. Interestingly, WPC made from non-
immunized animals also showed anti-inflammatory activity. The
presence of anti-inflammatory activity in the milk of
nonimmunized cows is not; surprising since it must be a natural
substance. Its detection reflects the sensitivity of the
bioassay.
Example 11
Continuous Monitorin4 of Carraaeenan Induced
Footoad Edema
It was established that 4 mg of MAIF given intravenously
at the time of carragee~nan injection reduced the accumulation
of edema in the footpad by between 40% and 50%. Although
these results provided evidence that the material contained
an anti-inflammatory moiety, there was little indication of
the site of action or pharmacological profile of MAIF. In
order to obtain such data it was necessary to establish a
method that allowed the continuous monitoring of footpad
edema throughout the response to carrageenan. This was
achieved by holding the rat foot in a demounted Gamma
radiation detector. The procedure required animals to be
anesthetized for up t~o four hours and, as anesthetics are
known to suppress the inflammatory response, it was first
necessary to determine the effect of anesthetics on the
carrageenan-induced edema. Five agents commonly used to
induce anesthesia in rats were therefore evaluated; these
WO 92/04035 PCT/US91 /I14174
2~J~0~~~1
-42-
were ether, chloral hydrate, Innovar-vet, nembutal and
urethane. The results are shown in Figure 15.
It was clear from these results that ether was the
anestheti c of choi ce whEan the i nfl artunatory response was to be
evaluated by this technique. The shape of the curve obtained
when ether was used indicated a biphasic response. To
delineate the response in more detail a further experiment
was carried out in which the volume of edema was measured at
12 time points over a 5~ hour period. The results confirmed a
biphasic response. The early response occurred between 0 and
1 hour after challenge and late phase response between 1.5 and
2 hours (Figure 16).
The two phases, which have also been observed by other
investigators, have been termed the non-phagocytic
inflammatory response (NPIR) and the phagocytic inflammatory
response (PIR), respectively.
The NPIR is initiated, in response to injury, by soluble
mediators such as histamine and bradykinin while the PIR
depends on the participation of neutrophils. The protocol,
therefore, was to administer MAIF and monitor the
accumulation of edema continuously in an effort to determine
whether the anti-inflammatory properties of the agent were a
result of an effect on the early non-cellular (NP1R) or the
later cellular (PIR) phase. 5 mg or 40 mg of MAIF/rat were
administered intravenously at the time of carrageenan
challenge and the accumulation of edema monitored at regular
intervals over a four hour period. Neither dose affected the
accumulation of edema du ring either phase (Figure 17).
This result was surprising as many previous analyses, in
which the effect of MAI'~~F on carrageenan induced oedema 4 hours
after challenge was determined, had demonstrated considerable
anti-inflammatory activity in the fraction. It was likely,
therefore, that the continuous exposure to ether suppressed or
WO 92'04035 PC1'/US91/0417a
-43-
inactivated the active anti-inflammatory component of MAIF in
vivo.
Previous studies indicated that short term exposure to
ether did not affect the activity of MAIF. Therefore, an
experiment was done in which the effect of MAIF on
progressive edema accumulation was determined at only four
time points, 0, 1, 3 and 4 hours, thus limiting the exposure
of the animals to ether. The 1 hour time point was chosen to
assess the affect on i:he early non-phagocytic inflammatory
response while the 3 and 4 hour measurements were selected to
quantify the effect on the later phagocytic inflammatory
response. In this experiment MAIF, administered at 40 mg
resulted in a reduction in the accumulation of edema during
the secondary, phagocytic-cell mediated phase, but had no
significant effect on the primary, soluble mediator driven
phase (Figure 18).
The following conclusions can be drawn from this series
of experiments.
1. Ether is the preferred anesthetic for use in experiments
where the inflammatory response to carrageenan is to be
monitored continuously.
2. Continuous ether anesthesia inhibits the in vivo anti-
inflammatory activity of MAIF in the carrageenan footpad
assay.
3. MAIF ameliorates inflammation by inhibiting the late,
phagocytic-cell mediated phase of the inflammatory
response to carrageenan.
. , )
rT~US9~~/04~7 ~
209001 1 lP~"''~~~ 3 0 SEPIg
92
-44- Substitute Sheet
Example 12
Time Course of the Effect of MAIF on
Carraqeenan Induced Footpad Edema
A further series of experiments were carried out in which
the agent was administered at selected time points before or
after the injection of carrageenan rather than at the time of
challenge. The purpose of the study was to provide information on
(a) the most effective time for administration of MAIF in
relation to the inflammatory stimulus.
(b) the biological half life of the anti-inflammatory
moiety.
(c) the points in the development inflammatory response
affected by MAIF.
The study was carried out in three parts. MAIF was administered
intravenously at a dose of 4 mg/rat at one of 11 time points,
ranging from 150 minutes before to 150 minutes after injection of
carrageenan. The results of this experiment are shown in Figure
19 and Table 5. .
Table 5
Time of
A in Mean foot Mean foot Inhibition
relation volume of volume of of edema
to control MAIF by MAIF
Experi-challenge groups groups (% of control
m n Lmin) ~~1 t SDJi ~(~,rl t volume t
SD) SD)
3 -150 311165 246152 79117
2 -90 304171 211133 73111
2 -60 304171 186134 61111
1 -30 391163 261149 67113
3 -15 311165 152141 49113
1,2,3 0 336178 184142 55113
3 15 311165 218130 70110
1 30 391163 218130 5618
2 60 304171 212140 69113
2 90 304171 216137 70112
3 150 311165 261142 84114
,. r,iir.~
_... ..i~~ ,_r-.~;;i~
;n
.1
WO 92/04036 PCT/LJS91/041?a
24~0~11
-45-
A significant inhibition of edema was observed at all
time points studied; however, the level of inhibition was less
at the outer extremes (~150 min). An interesting cyclic
response to MAIF administration was seen in those groups
treated closer to the point of challenge. The fact that MAIF
was more effective when given 30 minutes after challenge than
when given 15 minutes after challenge supports the concept
that the secondary, phagocytic-cell mediated, phase of the
response is inhibited by the agent. MAIF strongly inhibited
the response to carrageenan when administered 15 minutes
before or at the time of challenge. It is apparent,
furthermore, that the agent has a relatively long half life in
the serum (1-2h) and its effectiveness is related to the time
of challenge and the dynamic nature of the inflammatory
response.
It is thus surmised that the anti-inflammatory effect is
due to an effect on inflammatory cells, likely the
neutrophils.
Example 13
ffect of MAIF on the Reverse
Passive Arthus Reaction
The possibility that MAIF might affect neutrophil
involvement was investigated by evaluating the ability of the
material to modulate the reverse passive Arthus reaction
(RPA). This immune complex-induced response is primarily
neutrophil mediated and agents which affect the development
of the reaction do so via an effect on these cells. To induce
'~.r,ther RPA, rats were injected intradermally with rabbit
antibody. to ovalbumin and intravenously with native
ovalbumin. Ovalbumin/ov~albumin-antibody inanune complexes form
in and around the dermal blood vessel walls, host neutrophils
WO 92,04035 PC1'/US91 /04174
-46-
2p9001~~.
bind to the Fc portion of the antibody and an intense
inflammatory reaction is initiated. It should be noted that,
although the response is initiated by immune-complexes, it
takes place independently of the host's immune system.
Three parameters are used to quantify the RPA. These
are, (1) edema - measured using the accumulation of 1251-HSA,
(2) hemorrhage - assessed by in vivo pre-labelling RBC's with
59Fe and (3) neutrophil accumulation - measured by
determining tissue levels of the neutrophils specific enzyme
myeloperoxidase (MPO). These assays are known to those of
ordinary skill in the art.
Eighteen rats were divided into three groups of six.
Rabbit anti-ovalbumin (40 u1) was injected intradermally at
four sites on the back of each animal and 2 mg of ovalbumin
injected intravenously immediately afterwards. One group of
animals received no other treatment and served as controls.
The second group were injected intravenously with 20 mg of a
lactose preparation, while the final group were injected
intravenously with 20 mg of MAIF. Both lactose and MAIF were
administered with the ovalbumin. The severity of the reaction
was assessed 3.5 hours after challenge. When MAIF was
administered intravenously at a dose of 20 mg/rat prior to
the initiation of the RPA response, there was a highly
significant inhibition of the three parameters used to
measure the response (Table 6, Figure 20). The lactose control
material also caused a modest and marginally significant
suppression of neutrophil accumulation and hemorrhage. This
indicates that there is a small amount of anti-inflammatory
activity in normal milk.
WO 92/04035 ~PCT/US91 /0417:1
~D~UU11
-47-
Table 6
Neutrophil
accumulation: Haemorrhage:
Group nits of MPO u1 of Edema l~C of RBC
Control 0.30 ~ .157 107 t 29 4.8 t 3.1
Lactose 0.214 ~ .176** 104 t 23 3.0 t 1.5**
MAIF 0.056 t .013 60 t 27* 1.5 t 1.7*
* = p < 0.01
** ~ p < 0.05
As the neutrophil is the primary mediator of the RPA,
these results provided additional evidence that MAIF was
capable of inhibiting the inflammatory response via an effect
on neutrophil function.
Example 14
Effect of Mp,IF on Neutroohil Migration
from the Yasculature
In order to participate effectively in an inflammatory
response, neutrophils must first migrate from the vasculature
to the site of inflammation. To determine whether MAIF
interfered with neutrophil migration, a model of inflammation
employing the subcutaneous implantation of sterile
polyurethane sponges was used. The sponges are removed at
intervals after implantation and by weighing the sponges and
then extracting and counting the cells in the infiltrate, both
the fluid and cellular phase of the response can be
quantified. Twenty four hours after implantation >95% of the
cells found in the sponge are neutrophils.
Two experiments have been carried out. In the first,
animals were treated with either 5, 10, 20, or 40 mg of MAIF
at the time of sponge implantation. Sponges were removed 24
hours after implantat ion. Each group consisted of between 5
WO 92/04035 PCT/LJS91/0417.t
20~UU11
-48-
and 8 rats and two sponges were implanted in each animal. The
results are shown in Figure 21.
Twenty or 40 mg oi' MAIF, administered intravenously at
the time of sponge implantation, had a marked effect on the
ability of inflammatory cells to migrate. A less marked, but
equally significant, inhibition of fluid accumulation was
also seen. The two lower doses of MAIF had no demonstrable
effect in this model of inflammation.
A second experiment:, designed to delineate the temporal
relationship between 'the inflammatory challenge (sponge
implantation) and MAIF administration, was carried out. In
this study, 20 mg of MA:IF were administered intravenously 30,
60 or 120 minutes after sponge implantation. A fourth,
control, group were left untreated. There were five animals in
each group. Two sponges were implanted in each animal and
these were removed after 24 hours. The results are illustrated
in Figure 22. Included on this graph are results obtained
from a sample group of rats that received 20 mg of MAIF at the
time of implantation (see Figure 21).
Results from the 'time-course of the effect of MAIF on
carrageenan-induced footpad edema show MAIF to be
comparatively ineffective when administered 60 minutes or
later after challenge. It is noteworthy that while 20 mg of
MAIF is required to suppress the inflammation associated with
the sponge implantation, 4 mg is sufficient to inhibit the
carrageenan-induced edema. Without intending to be held to
this interpretation, this disparity may be related to the
different level of prow ocation presented to the host by the
two stimuli. The sponge implant is a relatively benign
stimulus which induces a slow inflammatory response and the
bulk of the cells accumulate between 8 and 16 hours after
implantation (Figure 23). On the other hand the subcutaneous
injection of carrageenan is a very strong stimulant which
WO 92,~0403s PCT/US91/04174
-49-
induces a correspondingly strong response over a relatively
short period (Figure 16).
Example 15
effect of MAIF on Circulating Leucocvtes
Several pharmacological agents can inhibit neutrophil
migration. While some., such as cyclophosphamide, are
cytoreductive and act by inhibiting hemopoiesis in the bone
marrow, other agents, such as steroids and the non-steroidal
anti-inflammatory drugs, have specific sites of action and do
not result in leucocytosis. It was important therefore to
determine the effect of MAIF on circulating white blood cell
numbers and ratios.
Two experiments we're done. In the first, MAIF was
administered intravenously at a dose of 40 mg/rat to one group
of 6 animals and a control group was injected with saline.
Blood samples were obtained at baseline, 1, 4, and 24 hours
after treatment. The results are summarized in Figure 24.
MAIF administration resulted in an increase in
circulating neutrophil numbers, maximal at 4 hours, and a
corresponding decrease in the number of peripheral blood
lymphocytes. A further dose-response study was carried out in
which a group of rats were injected intravenously with
saline, 5, 10 or 20 mg of MAIF. Blood from each rat had been
taken 7 days previously to provide baseline values and was
taken again 4 hours after the injection of MAIF. The results
are shown in Figure 25. Included on the graph are the
results obtained from 'the sample taken 4 hours after the
administration of 40 mg MAIF (see Figure 24).
All doses of MAIF resulted in an increase in the number
of circulating neutrophils and a decrease in the number of
lymphocytes. While they effect on lymphocytes was linearly
related to dose, the increase in neutrophil numbers was in
WO 92',/04035 PCT/US91/0417a
2~~~~i~
-50-
the form of a curve, tlhe greatest effect being observed in
those animals given 10 m~3.
These results support the concept that MAIF modulates
inflartmation by affectiing the adhesion of neutrophils to
endothelial cells.
Data were also obtained pertaining to the effect of
three other cell-targeted, anti-inflammatory/inmunomodulatory
agents on circulating leucocytes in the rat. The steroidal
drug, methylprednisolone, causes a change in the lymphocyte/
neutrophil ratio analogous to that seen with MAIF. The
temporal relationship between drug administration and effect
is somewhat different. The anti-rejection/anti-inflammatory
agent cyclosporin A also causes an increase in the number of
circulating neutrophils but lymphocyte numbers are either
increased or not affected depending on the dose. In
contrast, the cytotoxic drug cyclophosphamide depletes both
circulating lymphocytes and neutrophils. The effects of MAIF
would appear to closely parallel the action of methyl-
prednisolone.
Example 16
~uonression of Infection Induced Inflammation by MAIF
Experiments have been carried out to determine whether
changes in serum levels ~of acute phase reactants (APRs) could
be used to quantify the anti-inflanunatory activity of MAIF.
The APRs are a group of proteins which are synthesized in
response to an i nfl ammat~ory stimul us . One of these, al pha 2
macroglobulin, is common to both man and rats and methodology
for measuring this inflammatory component is available. Two
intravenous injections of MAIF (0 and 24 hours) did not
reduce the peak response (48 hours) of alpha Z macroglobulin.
This result indicates that MAIF does not affect the later
inflammatory response.
-~~~t~~s~ -_ m4 ~ 7 ~
..
209001 1 '' L~~~~ 30 SEP
X992
-51- Substitute Sheet
Example 17
In Vitro and In Vivo Evaluation of Milk
Derived Anti-Inflammatory Factor (Bovine
Mammary Macropha4e Assay, Infection Models in Mice],
Incubation of bovine mammary macrophages with the
hyperimmune milk fraction (MAIF) did not detectably enhance the
degree of phagocytosis but did increase the ability of
macrophages to kill phagocytosed Staphylococcus aureus. Mice
injected intraperitoneally with 10 mg MAIF per kilogram
demonstrated increased resistance to intraperitoneal challenge
with lethal Staphylococcus aureus.
In an intro-mammary Staphylococcus aureus mastitis
challenge model, MAIF injected mice also showed significantly
less mammary inflammation and involution and increased clearance
of the infectious organiam. Quantitative histological analysis
of mammary tissue from MAIF treated mice showed significantly
more lumen, less interalveolar connective tissue, and less
1 eukacyti c i of i 1 trati on compared to control mi ce . Mamunary g1 ands
of treated mice also contained fewer colony forming units than
control mice. MAIF appears to exert its effect on the non-
specific defense system by a modulation of leukocyte function.
Example 18
Effect of MAIF on the Pathogenesis of
Experimental Infection
The most conmon inflanmagens encountered by man are
microbial and it is important to determine the effect of any
agent which modulates Host defenses against infection. The
tissue damage which accompanies many infectious diseases is in
fact caused by the host response to infection rather than by
..,- - r.~
ww:v w~ IECT
~_ :, j ~'." ; ? ~ i i_ v!
IPEA/US
~,y_ / J41 l ~
2()9001 1 ~P~;~!'.~S 30 SEP19g2
-52- Substitute Sheet
the invading organism. While the ability to modulate the
inflammatory response to infection could be a useful clinical
technique, it must be recognized that inhibition of the host
response during infect ion can be disadvantageous. This is
especially true in the case of neutrophil inhibition. Studies
with agents which curb the participation of neutrophils in the
early stages of infection have demonstrated that, while
inflammation and tissue damage may be initially suppressed, the
increased bacterial load that occurs as a result of the reduced
cellular response eventual leads to an exacerbation of tissue
damage. Thus, it is essential to evaluate the potential of MAIF
-to modulate infection in order to (1) determine if the agent can
reduce infection-induced tissue damage and (2) to assess whether
any observed suppression of the host response is accompanied by
an increase in the severity of infection.
The effect of MAIF on edema formation following the
intradermal injection of E.E. coli 075 was determined. Two
groups of 8 animals were used. One group was untreated and
served as controls whiles individuals in the second group were
injected intravenously with 40 mg of MAIF in 0.5 ml saline.
Immediately after the administration of MAIF, 100 ,u1 of an
overnight culture of ~ coli 075 was injected intradermally
at two skin sites on the shaved back of the rat, followed by
the intradermal injection of 100 N1 of saline at two further
sites. To allow estimation of edema volume in the infected
skin, 0.1 NCi of ~6I-HSA was injected intravenously at the
time of challenge. :Six hours later the animals were
anaesthetized, a blood sample obtained, the skin on the back
removed and the infected and saline injected sites punched
out. The volume of edema was calculated by relating tissue
counts to plasma counts as described. To obtain the volume of
edema which accumulates as a result of the presence of coli
w : . L J!'~~fT
~' c'rv~~S
WO 92~~04035 2 p ~ ~ 011 P~/US91/04174
-53-
the edema/plasma volume of the saline-injected sites was
subtracted. The results are shown in Figure 26.
MAIF administration resulted in a 48f. inhibition of
edema formation. This experiment established that MAIF could
modulate the local inflammatory response to infection.
In order to study the relationships between MAIF
administration, bacterial replication, the accumulation of
fluid and inflammatory cell infiltration, an alternative
model of infection was employed. Polyurethane sponges,
prepared and implanted as. previously described, were infected
with a quantitated sample of ~. coli 075 at the time of
implantation. The sponges were removed at timed intervals,
weighed to determine the volume of the fluid exudate, and
then squeezed in media 1;o free the bacteria and cells from
the sponge. Bacterial and cell numbers were estimated using
techniques known to those skilled in the art. The following
experiment was carried out using this model. Ninety animals
were divided into two groups of 45. One of these groups was
untreated and served as controls. The second group were
injected intravenously with 40 mg of MAIF. The sponges were
then implanted subcutaneously and, at the time of
implantation, each sponge was inoculated with 105 . oli
075. Groups of 6-8 animals were killed at intervals
thereafter and the bacteriological status and the size of the
inflammatory infiltrate in the sponges determined. The
results are illustrated in Figures 27-29.
The rate of bacterial replication was much greater in
MAIF treated animals than in the controls and there was a 10,
1Q00 and 10,000 fold difference in bacterial numbers at 4, 8
and 16 hours respectively. Thereafter, bacterial numbers
declined, although there was still a large difference at 96
hours {Figure 27).
The early respon<.;e to infection is the critical
determinant in the outcome of an infectious episode. In this
WO 92/0403 PCT/US91 /04174
~~~~I~~~
-54-
experiment the cellular infiltrate at 2, 4 and 8 h in those
animals given MAIF was 27%, 35% and 46% of the control
infiltrate respective 1y (Figure 28B). The cells which
accumulate in the first 24 h after challenge are >90%
neutrophils and the suppression of this cellular component
during this phase may account for the rapid increase in
bacteri al numbers . They accumul ati on of fl ui d at 2 hours was
not affected by the administration of MAIF, but was
significantly less 4, 8 and 16 hours following challenge.
This is consistent with the previous finding that MAIF did not
suppress the primary, non-cellular phase of edema formation in
the carrageenan footpad model. In previous studies, using the
immunomodulatory agents cyclosporin A and methylprednisolone,
a similar association between the suppression of the acute
cellular inflammatory infiltrate and the promotion of
bacterial replication was shown. However, in these
experiments, the increased bacterial load promoted a host
response between 24 and 48 hours post challenge in which there
was a massive influx of neutrophils. When tissue was
involved, the enhanced inflammatory response resulted in a
marked exacerbation of tissue damage and scar formation.
Interestingly, although administration of MAIF suppressed the
early inflammatory response and was associated with a 10,000
fold increase in bacterial numbers there was no massive
influx of neutrophils 24-48 hours post challenge.
Example 19
Effect of MAIF on Experimental Pveloneohritis
An agent which can suppress inflammation in infection
without resulting in a sequela of enhanced tissue damage
would have considerable potential. A clinically relevant
model of infectious disease could provide an experimental
basis for establishing such potential.
WO 92/04035 ~ ~ PCT/US91 /0417:
-55-
Pyelonephritis is an infectious disease which
demonstrates local inflarnmation, tissue destruction and scar
formation as cardinal histological features. A well
characterized model of the disease is available, which
reproduces the central pathological features of the disease
in man. Pyelonephritis is induced in the rat by the direct
inoculation of the surgically exposed kidney with a
predetermined number of . coli 075. Following challenge,
bacterial numbers increase rapidly and reach a peak 3 to 4
days later. In normal animals the level of infection
declines over the following 5 or 6 days and reaches a plateau
at about 10 days post challenge. By 21 days the lesions have
resolved and present as focal areas of indented scar tissue.
To assess the effect of MAIF on this model of infection,
pyelonephritis was induced in both kidneys of twenty-six
animals. One half of these animals were treated with MAIF
intravenously at a dose of 40 mg/rat at the time of challenge
and again 48 hours later. Seven animals from each group were
killed 4 days after induction of pyelonephritis and the two
remaining groups of six animals at 21 days. Kidneys were
removed aseptically and weighed to determine the relative
vcaume of the fluid exuda~te. The extent of the surface lesion
size was estimated by direct visualization and the kidney
homogenized to allow the enumeration of bacterial numbers.
The results are shown in Figure 30.
Four days after challenge the inflammatory response, as
evidenced by the inhibition of fluid accumulation and the
size of the lesions on the surface of the kidney, was
suppressed by the administration of MAIF. As previously
observed in the studies involving infected, subcutaneously-
implanted sponges, the early suppression of inflammation
resulted in a logarithmic increase in the number of bacteria
in MAIF-treated animals. By 21 days there was no difference
in the pathology of disease as measured by kidney weight,
WO 9;/04035 PCT/LJS91/04174
20900~u
-56-
bacterial numbers or renal surface lesions size. Thus, while
suppression of the early inflammatory response with MAIF did
not result in a reduction in tissue destruction in the
chronic (21 day) phase of pyelonephritis, neither did it
promote the development of pathological lesions as other
anti-inflartmatory and iimnunomodulatory agents have done.
Example 20
Summarr~ of Experimental Data
A method was developed which allowed the accumulation of
edema in the carrageenan injected footpad to be monitored
continuously.
The early, non-phagocytic, phase of the inflammatory
response was not affected by MAIF, whereas the later,
cellular-driven, phase of the reaction was significantly
inhibited. Further experiments, in which MAIF was
administered at intervals before or after the injection of
carrageenan, provided additional evidence that MAIF exerted
its anti-inflammatory effect by modulating the secondary,
neutrophil-mediated, inflammatory response.
MAIF was shown to have a half-life of 1-2 hours following
i.v. injection and development of inflammation could be
suppressed when the agent was administered 30 minutes after
challenge. This result is relevant to the potential
therapeutic use of MAIF.
The neutrophil is; the principal cell involved in the
acute inflammatory response. During the Arthus reaction, a
>80% reduction in neutrophil accumulation was observed
following MAIF administration which, in turn, was associated
with a highly significant inhibition of the secondary
characteristics of the inflammatory reaction, namely edema and
hemorrhage. This result further implicated neutrophils as a
target in MAIF-induced suppression of inflammation.
WO 92/04036 PCT/US91 /04174
2U90~1~
-s7-
One of the key steps in the development of inflammation
is the migration of neutrophils from the vasculature to the
tissue. The intravenous administration of MAIF was shown to
result in profound and dose dependent inhibition of neutrophil
migration. When the effect of MAIF on peripheral blood
leucocytes was investigated, a marked increase in the number
of circulating neutrophils was observed, accompanied by a
corresponding decrease in the number of lymphocytes. This
effect was also dose-dependent, but in the case of the
increase in neutrophil numbers, was not linear.
Finally, the agent ignificantly suppressed the early
cellular response to infection, an effect which resulted in a
logarithmic increase in bacterial numbers in a model of
subcutaneous infection. This exacerbation of infection did
not result in a rebound of the inflammatory response, as seen
with other agents which suppress acute inflammation in
infection. A second experiment using a clinically relevant
model of infection, pye~lonephritis, also demonstrated a
suppressive effect on inflammation which was associated with
an increase in bacterial numbers. Again no rebound effect was
observed and there was no difference in the degree of tissue
damage which occurred in the MAIF treated and control groups.
The following conclu:>ions can be drawn from this series
of experiments:
1. MAIF, administered i.v., suppresses the secondary,
neutrophil-mediated, phase of the carrageenan induced
inflammatory response.
2. When evaluated in the carrageenan footpad assay MAIF has
a biological half- life of 1-2 hours and is effective
even when administered after inflammation is induced.
Subsequent experiments indicate that the effective half-
life is dependent on both the dose and inflammatory
stimulus employed.
3. MAIF inhibits neutrophil emigration in vivo.
WO 92/04035 PCT/US91/04174
-58-
249001.1
4. MAIF administration results in an increase in the number
of circulating neutrophils and a corresponding decrease
in lymphocyte numbers.
5. MAIF suppresses host defenses against infection,
probably via an efiFect on neutrophil emigration.
The experimental data obtained in these studies
demonstrate clearly that MAIF has a marked effect on the
neutrophilic component of the inflammatory response. The
effects we have observed to date may be the result of a
direct effect of MAIF on neutrophils per se, or the result of
the suppression (or stimulation) of some other cellular or
soluble mediator which indirectly alters the neutrophilic
response. It is also widely accepted that few
pharmacological agents are monospecific in their actions and
i t i s possi b1 a that MA I F wi 11 be found to affect a number of
different biological processes.
Having now generally described this invention, it will
become readily apparent to those skilled in the art that many
changes and modifications can be made thereto without
affecting the spirit or scope thereof.
